Pharma

Pharma

Cost of disease-modifying therapies for multiple sclerosis continues to rise in US, finds GlobalData

The cost of disease-modifying therapies (DMTs) for multiple sclerosis (MS) patients in the US has increased since 2020, placing an increasing financial strain on patients, their families, and the healthcare system, says GlobalData, a leading data and analytics company. According to GlobalData’s recent ‘Multiple Sclerosis: Seven-Market Drug Forecast and Market Analysis to 2030 – Update’ […]

Pharma

Immuno-oncology agents to continue transforming cancer treatment landscape, says GlobalData

Immuno-oncology (IO) agents have transformed the oncology landscape in the last decade, particularly immune checkpoint inhibitors (ICIs) in solid tumor settings and chimeric antigen receptor (CAR) T-cells in hematological malignancies, with patients who previously had very limited therapeutic options achieving long term remissions and even cure. Continued investment into IO R&D in both academia and […]

Pharma

Farxiga’s expanded approval highlights potential to differentiate in HF space, says GlobalData

Farxiga’s (dapagliflozin) recent approvals will help a broader range of patients with heart failure (HF) in the US. Resultantly, AstraZeneca is expected to see a significant boost in its revenues. Farxiga is expected to have such a strong influence on the market due to the impressive results and valuable evidence seen in recent trials. The […]

Pharma

Novavax AI approach to COVID-influenza vaccine design pays off in Phase II trial, says GlobalData

Artificial intelligence (AI) has been fundamental to the development of Novavax’s COVID-Influenza Combination (CIC) vaccine reflecting a wider industry trend for increased usage of AI in clinical trial design, says GlobalData, a leading data and analytics company. Novavax has recently announced topline results from a Phase II trial for its CIC vaccine. The data indicates […]

Pharma

Novo Nordisk’s blockbuster Ozempic sales to surge by 23% in 2023, forecasts GlobalData

Novo Nordisk’s leading drug Ozempic (semaglutide) is forecast to demonstrate a growth of 23% in its sales to $12.5 billion in 2023, consolidating its position as the dominant market leader, as projected sales will be 54% greater than closest competitor Trulicity (dulaglutide) by Eli Lilly, which anticipates sales of $8 billion, says GlobalData, a leading […]

Pharma

Ultragenyx’s UX053 Phase I/II study termination a minor setback for mRNA therapeutics, says GlobalData

Ultragenyx has terminated its Phase I/II trial for pipeline candidate UX053, a non-vaccine mRNA therapeutic for glycogen storage disease type III, also known as Cori’s disease. The study was terminated due to reasons unrelated to safety concerns, although the specific rationale has not been disclosed by the biopharmaceutical company. mRNA therapeutics hold a lot of […]

Pharma

National Lipid Day a timely reminder of dyslipidemia, says GlobalData

National Lipid Day, observed on 10 May every year creates awareness of dyslipidaemia, says GlobalData, a leading data and analytics company. Dr Shireen Mohammad, Cardiovascular & Metabolic Disorders Analyst at GlobalData, comments: “An unmet need in the dyslipidemia space is patient education and National Lipid Day is a great way to raise awareness for this […]

Pharma

GlobalData forecasts Immunogen’s Elahere sales to reach $615 million by 2029

US-based Immunogen recently announced positive top-line data from their Phase III MIRASOL trial evaluating Elahere (mirvetuximab) for the treatment of platinum-resistant ovarian cancer. The company plans to use the data to support their forthcoming supplemental Biologics Licensing Application for full FDA approval. Elahere’s sales are expected to reach $615 million by 2029, registering a 114% […]

Pharma

Bristol Myers Squibb’s Sotyktu for psoriasis to see $2.9bn in sales by 2029, forecasts GlobalData

Bristol Myers Squibb (BMS) recently announced the European Commission approval for Sotyktu (deucravacitinib), its first-in-class, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor for adults with moderate-to-severe plaque psoriasis (PsO). Representing a new class of small molecules with a unique mechanism of action, Sotyktu is set to become a blockbuster for the treatment of PsO with […]

Pharma

FDA accelerated approval of Biogen Qalsody game changer for rare subgroup of ALS patients, says GlobalData

The US Food and Drug Administration (FDA) has recently granted accelerated approval for Biogen’s Qalsody (tofersen), a drug that targets a specific group of amyotrophic lateral sclerosis (ALS) patients who have a superoxide dismutase 1 (SOD1) gene mutation. This decision is considered a game changer for this rare subgroup of ALS patients and sets a […]

Pharma

Brexit and COVID-19 caused greatest negative impact on UK healthcare sector, finds GlobalData

While some believed that leaving the EU would bring opportunities for the UK and its life sciences sector, three years on since the UK departed from the EU, Brexit and COVID-19 were highlighted as the events having the most negative impact on the UK healthcare sector, in a survey conducted by GlobalData, a leading data […]

Pharma

GlobalData forecasts oncology drug sales to generate $2.2 trillion between 2023 and 2029

In the race to combat cancer, the field of oncology has experienced strong growth in recent years. With forecasts pointing towards a continued upward trend, it is no surprise that the oncology market has emerged as the largest therapy area by sales, poised to generate $2.2 trillion in sales between 2023 and 2029. This significant […]

Pharma

Lack of innovation means checkpoint inhibitor trials continue to focus primarily on PD-1/L1, says GlobalData

Over 95% of the ongoing Phase III trials in the US featuring an immune checkpoint modulator involve either a PD-1 or PD-L1-targeting drug. Given the proven efficacy of these targets this is not necessarily surprising. However, for patients unable to tolerate, or refractory to these drugs, this lack of innovation is disappointing, says GlobalData, a […]

Pharma

GlobalData stresses need for patient education with injectable levodopa infusions for Parkinson’s disease treatment

Safety data on AbbVie’s ABBV-951 (foslevodopa/foscarbidopa) and NeuroDerm’s ND0612 (levodopa/carbidopa) for the treatment of Parkinson’s disease (PD) were showcased at the American Academy of Neurology (AAN) 2023 Annual Meeting. Should they receive FDA approval, these innovative levodopa delivery systems could offer an improved route of administration and will create additional options to control various motor […]

Pharma

Astellas acquisition of Iveric Bio to boost ophthalmology portfolio, expected to achieve leadership position in geographic atrophy, says GlobalData

Following the news that Japan-based Astellas Pharma entered into a definitive agreement to acquire US-based biopharmaceutical company Iveric Bio for $5.9 billion to create a world class ophthalmology entity; Prashant Khadayate, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “Astellas mentions blindness and regeneration as one of the five focus […]

Pharma

Majority of UK physicians believe Brexit aggravated NHS staff shortage crisis, finds GlobalData

UK healthcare professionals (HCPs) believe that Brexit had exacerbated the National Health Service (NHS) staffing crisis, according to a survey by GlobalData, a leading data and analytics company. In a GlobalData’s survey* titled “Brexit and the Healthcare Industry”, a total of 92% of surveyed physicians believed that Brexit had a negative impact on NHS staff […]

Pharma

Healthcare industry professionals feel more negative towards Brexit, finds GlobalData survey

More than half of the surveyed healthcare industry professionals indicated that their sentiment on the impact of Brexit on the UK’s healthcare sector became more negative, according to a survey* by GlobalData. The leading data and analytics company notes that 54% of healthcare industry professionals in the survey believed that their sentiment worsened three years […]

Pharma

Yasmin and Mirena to take back seat from Bayer’s future drug strategy, says GlobalData

German drugmaker Bayer recently announced that it will shift the focus of its drug research away from women’s health to four core therapeutic areas: oncology, cardiovascular, neurology, and rare diseases/immunology. In the women’s health space, the company has a presence with its Yasmin brand of birth-control pills and the intrauterine device Mirena. The news of […]

Pharma

As Cytokinetics ALS drug fails Phase III trial, attention turns to cardiomyopathy candidate aficamten, says GlobalData

Cytokinetics, a San Francisco-based biotechnology company, is set to wind down the Phase III trial of its amyotrophic lateral sclerosis (ALS) pipeline drug, reldesemtiv, as there is no evidence of an effect compared to placebo on primary or secondary endpoints. This comes after the pharma company announced the FDA had rejected its heart failure drug, […]

Pharma

Cipla continues to strengthen anti-diabetes innovative portfolio through partnerships with MNCs in India, says GlobalData

Cipla holds a prominent position in the top five therapy areas in India, except for the anti-diabetes and gastrointestinal segment. Against this backdrop, the Indian pharma major is constantly partnering with multinational companies to get access to an innovative portfolio with a focus on diabetes, says GlobalData, a leading data and analytics company. Cardiology, anti-diabetes, […]

Prev 1 … 34 35 36 37 38 … 108 Next

Cost of disease-modifying therapies for multiple sclerosis continues to rise in US, finds GlobalData

Immuno-oncology agents to continue transforming cancer treatment landscape, says GlobalData

Farxiga’s expanded approval highlights potential to differentiate in HF space, says GlobalData

Novavax AI approach to COVID-influenza vaccine design pays off in Phase II trial, says GlobalData

Novo Nordisk’s blockbuster Ozempic sales to surge by 23% in 2023, forecasts GlobalData

Ultragenyx’s UX053 Phase I/II study termination a minor setback for mRNA therapeutics, says GlobalData

National Lipid Day a timely reminder of dyslipidemia, says GlobalData

GlobalData forecasts Immunogen’s Elahere sales to reach $615 million by 2029

Bristol Myers Squibb’s Sotyktu for psoriasis to see $2.9bn in sales by 2029, forecasts GlobalData

FDA accelerated approval of Biogen Qalsody game changer for rare subgroup of ALS patients, says GlobalData

Brexit and COVID-19 caused greatest negative impact on UK healthcare sector, finds GlobalData

GlobalData forecasts oncology drug sales to generate $2.2 trillion between 2023 and 2029

Lack of innovation means checkpoint inhibitor trials continue to focus primarily on PD-1/L1, says GlobalData

GlobalData stresses need for patient education with injectable levodopa infusions for Parkinson’s disease treatment

Astellas acquisition of Iveric Bio to boost ophthalmology portfolio, expected to achieve leadership position in geographic atrophy, says GlobalData

Majority of UK physicians believe Brexit aggravated NHS staff shortage crisis, finds GlobalData

Healthcare industry professionals feel more negative towards Brexit, finds GlobalData survey

Yasmin and Mirena to take back seat from Bayer’s future drug strategy, says GlobalData

As Cytokinetics ALS drug fails Phase III trial, attention turns to cardiomyopathy candidate aficamten, says GlobalData

Cipla continues to strengthen anti-diabetes innovative portfolio through partnerships with MNCs in India, says GlobalData

Browse

Company information